Myasthenia gravis with thymus hyperplasia

Summary

Myasthenia gravis with thymus hyperplasia (MONDO:0011768) is a disease. A subtype of myasthenia gravis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myasthenia gravis with thymus hyperplasia
Mondo ID	MONDO:0011768
MeSH	C564628
OMIM	607085
UMLS	C1846838
MedGen	375982
GARD	0024823
Is cancer (heuristic)	no

Also known as: myasthenia gravis with thymus hyperplasia

Disease family

This is a subtype of myasthenia gravis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › autoimmune disorder of the nervous system › autoimmune disorder of peripheral nervous system › myasthenia gravis › myasthenia gravis with thymus hyperplasia

Related subtypes (5): neonatal myasthenia gravis, myasthenia, limb-girdle, autoimmune, adult-onset myasthenia gravis, juvenile myasthenia gravis, transient neonatal myasthenia gravis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.